R&D-only biopharma inventing oncology/immunology drugs, licensed out to Sun Pharma and other partners.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 26 | 26 | 27 | 32 | 32 | 32 | 32 | 32 |
| Reserves | -45 | -194 | 4 | 480 | 93 | -249 | -381 | 1.3k |
| Borrowings | 67 | 236 | 79 | 16 | 61 | 269 | 417 | 559 |
| Other Liabilities | 224 | 162 | 170 | 302 | 328 | 284 | 252 | 273 |
| Total Liabilities | 273 | 230 | 280 | 830 | 515 | 336 | 320 | 2.2k |
| AssetsFixed Assets | 104 | 91 | 92 | 106 | 108 | 99 | 162 | 85 |
| CWIP | 32 | 5 | 26 | 27 | 44 | 54 | 1 | 72 |
| Investments | 8 | 6 | 12 | 291 | 2 | 0 | 0 | 0 |
| Other Assets | 128 | 127 | 150 | 406 | 362 | 183 | 156 | 2.0k |
| Total Assets | 273 | 230 | 280 | 830 | 515 | 336 | 320 | 2.2k |
| Line item | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| ActivitiesCash from Operating | -172 | -211 | -152 | -208 | -69 | -429 | -360 | -239 |
| Cash from Investing | -102 | 155 | 2 | -29 | -548 | 392 | 158 | -23 |
| Cash from Financing | 274 | 55 | 159 | 229 | 617 | 42 | 199 | 261 |
| SummaryCapital Expenditure | — | — | — | — | — | — | — | — |
| Free Cash Flow | -184 | -264 | -153 | -233 | -84 | -455 | -370 | -262 |
| FCF Margin | — | — | — | — | — | — | — | — |
This looks cyclical, and we don't have enough quarters to establish a through-cycle earnings base. Valuing it off the current point in the cycle would be misleading.
SPARC · CYCLICAL_UNMODELABLE
Guides on how to read this kind of business and the numbers that matter.